Table 2.

Baseline Characteristics of patients with Hepatitis C and Thalassemia Major Treated With Directly Acting Antivirals (DAA).

Age in years (mean ± SD)	24 ± 5.1
Gender (M:F)	16:13
Body mass index (kg/m2) (mean ± SD)	19.4 ± 2.9
Splenectomy (n)	9
Diabetes (n)	6
Hypothyroidism (n)	4
Thrombocytopenia (<150 × 109/l)	4
Chelation (15 patients received 2 chelators)
Deferoxamine (n)	10
Weekly vials (mean ± SD)	10.1 ± 5.1
Deferiprone (n)	13
Daily dose (mg) (mean ± SD)	2807 ± 878
Deferasirox (n)	21
Daily dose (mg) (mean ± SD)	1533 ± 502
Transfusion requirement (ml/month) (mean ± SD)	896 ± 199
T2* MRI heart iron overload (n = 24) score ≥2	6
T2* MRI Liver iron overload (n = 24) score ≥2	16
Serum ferritin (ng/ml) (mean ± SD)	5381 ± 4198
Fasting sugar (mg/dl) (mean ± SD)	98 ± 25
2 h post-prandial sugar (mg/dl) (mean ± SD)	117 ± 39
Hepatitis C RNA (IU/ml) (mean ± SD)	1.82 ± 3.05 × 106
Genotype 1 (n) (a/b)	17 (7/10)
Treatment naïve (n) (a/b)	10 (5/5)
Treatment experienced (n) (a/b)	7(2/5)
Genotype 3 (n)	11
Treatment naïve (n)	10
Treatment experienced (n)	1
Treatment experienced (n)	8
Partial responder (n)	3 (all genotype 1)
Null responder (n)	1 (genotype 3)
Relapse (n)	4 (all genotype 1)
Recurrence (n)	0
Cirrhosis (n)	6
Fibroscan (kPA) (mean—range)	14.12 (3.3–29.5)
AST (IU/l) (mean ± SD)	64 ± 49
ALT (IU/l) (mean ± SD)	59 ± 33
ALP (IU) (mean ± SD)	107 ± 81
Hb (g/dl) (mean ± SD)	8.8 ± 1.0
Platelets (per litre) (mean ± SD)	298 ± 151 × 109
Albumin (g/dl) (mean ± SD)	4 ± 0.4
Creatinine (mg%) (mean ± SD)	0.6 ± 0.1
Bilirubin (mg/dl) (mean ± SD)	1.7 ± 0.8

T2* MRI score >2 implies significant iron overload.

SD, standard deviation; AST, aspartate amonotransferase; ALT, alanine aminotransferases; ALP, alkaline phosphatase; WCC, white cell count; Hb, haemoglobin.

1 patient had a unclassified genotype and was treated with sofosbuvir and daclatasvir and was treatment naïve.